Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 4, 2006Clinical Infectious DiseasesOpen Access

Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study

View Full Paper
Ask AI
Bookmark
Share

Authors

HRHeather J. RibaudoCancer Research And BiostatisticsDHDavid W. HaasMeharry Medical CollegeCTC. TierneyBoston University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ribaudo et al. (2006) studied this question.

synapsesocial.com/papers/6a9b247a804355db1ffcee00https://doi.org/10.1086/499364
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Population Pharmacokinetics and Pharmacodynamics of Efavirenz, Nelfinavir, and Indinavir: Adult AIDS Clinical Trial Group Study 3982002 · 129 citations
  2. 2Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy2000 · 272 citations
  3. 3Population pharmacokinetic meta-analysis with efavirenz2002 · 84 citations
  4. 4Pharmacokinetic and Pharmacodynamic Characteristics of Emtricitabine Support Its Once Daily Dosing for the Treatment of HIV Infection2004 · 110 citations
  5. 5Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals2005 · 272 citations